Sanofi update on Zantac litigation Paris, May 31, 2024. Sanofi is disappointed with the State of Delaware court’s decision not to exclude plaintiffs’ experts from the cases and intends to appeal.

Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase ...

Paris, May 31, 2024. Sanofi’s global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries. Now in its 10 th year, the program demonstrates the ...

Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, . Sanofi, Formation Bio and OpenAI are collaborating to ...

Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from ...

New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma          Late-breaking data presented at ATS show that treatment ...

Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and ...